ForDoz Pharma announced today that it entered into an agreement with LipoMedix to manufacture its lead compound for a clinical trial.
LipoMedix’s pegylated liposomal Promitil (PL-MLP) is designed for the selective delivery of the therapeutic agent to cancer-affected tissues and is suited for cancer chemoradiotherapy, according to a news release.
Studies have shown PL-MLP to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug-resistant tumors, the companies say.
“We continue to move full-steam ahead, knowing that the patients we can help with Promitil have been long awaiting a low-toxicity and effective treatment option,” LipoMedix president & chief scientific officer Dr. Alberto Gabizon said in the release. “We are thinking long term when selecting our partnerships and look forward to partnering with ForDoz on the next phase of our journey to bring Promitil to those who need it most.”
East Windsor, N.J.-based ForDoz is a specialty pharmaceutical company focusing on developing, manufacturing and commercializing value-added sterile and complex injectable products, including liposomes, microspheres, micelles, nanosuspensions and microcrystal-suspensions.
“Our mission is to ultimately aid in the delivery of innovative medicines that will help people live longer and better lives,” ForDoz founder & CEO James He said. “We are proud to partner with LipoMedix to help them develop and manufacture Promitil here in the United States.”
